Decentralized Clinical Trials
ARG’s decentralized clinical trial (DCT) model helps our sponsors recruit more diverse populations, retain more patients and discover more valuable data.
Decentralization Delivers Better Data For Faster Trials
Over the past decade, there has been a marked shift toward a more decentralized and patient-centric approach to clinical trials. In addition, the emergence of Covid-19 led to a drastic change in the clinical research landscape resulting in widespread adoption of decentralized trial methodologies across the industry.
Technology is already well-entrenched across all aspects of health care, so it should not be a surprise to imagine that the technology-based clinical trial model is becoming the standard. The guidelines released by regulatory authorities indicate the plausibility of using technology-driven studies to overcome the limitations of conventional trials.
Decentralization leverages technology to provide savings in every aspect of the clinical trial. Recruitment costs can be sustainably lower due to participation through ePro, wearable devices and telehealth visits. Administrative and site monitoring costs are reduced simply by lowering the number of site visits through the use of DDC and telehealth.
Benefits Of Decentralized Trials
The Benefits & Challenges Of DCTs
Differing from traditional clinical studies, DCTs employ a more patient-centric approach, which promotes higher subject recruitment and retention rates by minimizing barriers to participation. The study design also saves time for patients by reducing travel burden and utilizing engaging trial technologies.
The merits of DCTs are not limited to study participants only. Sponsors also benefit from decentralized trials with reduced costs, less travel time required, enhanced data accuracy, and real-time data monitoring.
Decentralized vs. Traditional Trials
DCTs refer to human clinical studies carried out by local and mobile health care providers who use methodologies and technologies different from those in traditional clinical trials, such as telemedicine.
Unlike the traditional approaches, DCT focuses on incorporating local and mobile caregivers into clinical trials with the aid of novel information technology.
9 Keys to Decentralized Trials
According to a June 2020 SCRS survey, only 40% of clinicians have participated in a hybrid DCT or a virtual clinical trial. This reluctance in adoption may be due to the perceived complexities of setting up and running decentralized trials.
Fortunately, DCTs don’t have to be complicated. Let’s review some of the best practices and key questions involved with decentralization.